Prime Therapeutics backs first interchangeable insulin biosimilar Semglee®
Biosimilars, which are biologic drugs, treat conditions such as diabetes, multiple sclerosis, rheumatoid arthritis and cancer. Biologic drugs are large molecule drugs with complex mechanisms of action (living cells or complex proteins), and they are often genetically modified in some way. ¹ An FDA biosimilar approval means there is no clinically meaningful difference between a biosimilar and its biologic reference product. The biosimilar delivers the same quality, safety, purity, potency and effectiveness. ²
Biosimilars often have initial prices that are 15% to 35% lower than the reference products, which is particularly important as drug costs continue to increase, and specialty drugs now represent more than 50% of the health care dollar.
Preferring biosimilars across numerous treatment categories can save health plans and their members hundreds of millions of dollars. In particular, treatment costs in the diabetes population continues to rise, so having a biosimilar replace a brand product will yield significant savings.
"This formulary change reinforces Prime's commitment to increasing biosimilar adoption and also demonstrates that we are not beholden to rebates, as we're able to also prefer the lowest net cost therapy," noted
"This is really great news for people living with diabetes as biosimilars can deliver savings for patients without sacrificing safety and efficacy," said
Prime anticipates no significant member disruption and affordability will be comparable or better with the biosimilar. Prime's clients can choose its national formulary strategy for their commercial and
Earlier this year, Prime launched MedDrive™ medical drug management solutions, a new product which focuses on drug savings strategies through greater biosimilar drug adoption, most which are paid on the medical benefit. Other elements of MedDrive include benefit designs that prefer lowest net cost non-biosimilar drugs, plus enhancements to predictive data analytics, medical sourcing opportunities, and consultation services. For more on Prime's efforts around biosimilars:
Read Prime's whitepaper.- Listen to the PCMA podcast.
- Watch this webinar.
1. What is a biosimilar?
2.
About Prime Therapeutics
Contact:
612.777.5742
klyons@primetherapeutics.com
View original content:https://www.prnewswire.com/news-releases/prime-therapeutics-backs-first-interchangeable-insulin-biosimilar-semglee-301414871.html
SOURCE


ACNB Corporation Reports 2021 Third Quarter and Year-to-Date Financial Results
Fannie Mae Does Credit Insurance Risk Transfer Deal On $32B Of Loans
Advisor News
- SEC settlement would require Tai Lopez, two others, to pay $6.8 million
- The Gen Z money paradox
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
- Election results cloud retirement legislation outlook, experts say
More Advisor NewsAnnuity News
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- Boomers want retirement protection, but their actions don’t match their mindset
- NAIC task force to address LTC riders
- ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
More Annuity NewsHealth/Employee Benefits News
- Picking Medicare insurance plan is daunting task – Healthful Hints
- November Issue of Best’s Review Ranks US Life Reinsurers and More
- New York Life Announces Record $3.1 Billion in Policy Owner Dividends for 2027
- New Va. subsidies help lure people back to health insurance
- 3 ways Crowley can make Healthcare more affordable in Wisconsin
3 ways to make healthcare more affordable in Wisconsin | Coleman Drake (Copy)
More Health/Employee Benefits NewsLife Insurance News
- November Issue of Best’s Review Ranks US Life Reinsurers and More
- Nebraska widow’s big win against life insurer in legal limbo
- New York Life Announces Record $3.1 Billion in Policy Owner Dividends for 2027
- AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
- U-Haul Holding Company to Participate in Deutsche Bank Conference
More Life Insurance News